medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2022, Number 4

<< Back Next >>

Medicina & Laboratorio 2022; 26 (4)

Subacute thyroiditis and thyrotoxicosis after SARS-CoV-2 vaccine: report of 2 cases

Rueda-Galvis MV, Ramírez-Sánchez IC, Builes-Montaño CE, Vélez-Hoyos A

Language: Spanish
References: 21
Page: 383-389
PDF size: 191.50 Kb.


ABSTRACT

The SARS-CoV-2 coronavirus disease which emerged in 2019 (COVID-19), has forced the rapid development of vaccines to prevent the spread of infection and attempt to control the pandemic. Among the vaccines developed, one of the first to be approved with a new technology in the field of vaccination, was the mRNA (messenger ribonucleic acid) vaccine, with rates of effectiveness close to 95% for the prevention of severe COVID-19 disease. Common adverse events are mild local reactions, but there have been some reports of patients developing sub- acute thyroiditis and thyroid dysfunction after receiving the SARS-CoV-2 vaccine. This article presents two case reports of subacute thyroiditis shortly after receiving the COVID-19 vaccine.


REFERENCES

  1. Ritchie H, Mathieu E, Rodés-Guirao L, AppelC, Giattino C, Ortiz-Ospina E, et al. Coronaviruspandemic (COVID-19). Wales, England:Our World in Data. Acceso 14 de enero de 2022. Disponible en https://ourworldindata.org/coronavirus#citation.

  2. Lui DT, Lee CH, Chow WS, Lee ACH, Tam AR,Fong CHY, et al. Thyroid dysfunction in relationto immune profile, disease status, and outcomein 191 patients with COVID-19. J Clin EndocrinolMetab 2021;106:e926-e935. https://doi.org/10.1210/clinem/dgaa813.

  3. Braverman L, Utiger R, Lewis E, JH Lazarus,Lippincott W. Silent thyroiditis and subacutethyroiditis. In: Sidney H. Ingbar, Sidney C. Werner,eds. Werner and Ingbar's the Thyroid: AFundamental and Clinical Text. 7th ed. Philadelphia:Lippincott Williams & Wilkins; 1996.p. 577.

  4. Christensen J, O'Callaghan K, Sinclair H,Hawke K, Love A, Hajkowicz K, et al. Riskfactors, treatment and outcomes of subacutethyroiditis secondary to COVID-19: a systematicreview. Intern Med J 2022;52:522-529.https://doi.org/10.1111/imj.15432.

  5. Brüssow H. COVID-19: vaccine's progress. MicrobBiotechnol 2021;14:1246-1257. https://doi.org/10.1111/1751-7915.13818.

  6. Altay FA, Güz G, Altay M. Subacute thyroiditisfollowing seasonal influenza vaccination.Hum Vaccin Immunother 2016;12:1033-1034.https://doi.org/10.1080/21645515.2015.111

  7. 7716.7. Hernán-Martínez J, Corder E, Uzcátegui M,García M, Sostre S, García A. Subacute thyroiditisand dyserythropoesis after influenza vaccinationsuggesting immune dysregulation. BolAsoc Med P R 2011;103:48-52.

  8. Bornemann C, Woyk K, Bouter C. Case report:two cases of subacute thyroiditis followingSARS-CoV-2 vaccination. Front Med (Lausanne)2021;8:737142. https://doi.org/10.3389/fmed.2021.737142.

  9. Polack FP, Thomas SJ, Kitchin N, Absalon J,Gurtman A, Lockhart S, et al. Safety and efficacyof the BNT162b2 mRNA COVID-19 vaccine.N Engl J Med 2020;383:2603-2615. https://doi.org/10.1056/NEJMoa2034577.

  10. Voysey M, Costa-Clemens SA, Madhi SA,Weckx LY, Folegatti PM, Aley PK, et al. Singledoseadministration and the influence of the timingof the booster dose on immunogenicityand efficacy of ChAdOx1 nCoV-19 (AZD1222)vaccine: a pooled analysis of four randomisedtrials. Lancet 2021;397:881-891. https://doi.org/10.1016/s0140-6736(21)00432-3.

  11. Frenck RW, Jr., Klein NP, Kitchin N, GurtmanA, Absalon J, Lockhart S, et al. Safety, immunogenicity,and efficacy of the BNT162b2 COVID-19 vaccine in adolescents. N Engl J Med2021;385:239-250. https://doi.org/10.1056/NEJMoa2107456.

  12. Barda N, Dagan N, Ben-Shlomo Y, KeptenE, Waxman J, Ohana R, et al. Safetyof the BNT162b2 mRNA COVID-19 vaccinein a nationwide setting. N Engl J Med2021;385:1078-1090. https://doi.org/10.1056/NEJMoa2110475.

  13. Vera-Lastra O, Ordinola-Navarro A, Cruz-Domiguez MP, Medina G, Sánchez-ValadezTI, Jara LJ. Two cases of Graves' disease followingSARS-CoV-2 vaccination: an autoimmune/inflammatory syndrome induced by adjuvants.Thyroid 2021;31:1436-1439. https://doi.org/10.1089/thy.2021.0142.

  14. İremli BG, Şendur SN, Ünlütürk U. Threecases of subacute thyroiditis following SARSCoV-2 vaccine: Postvaccination ASIA syndrome.J Clin Endocrinol Metab 2021;106:2600-2605.https://doi.org/10.1210/clinem/dgab373.

  15. Franquemont S, Galvez J. Subacute thyroiditisafter mRNA vaccine for COVID-19. J Endocr Soc2021;5:SA956-957. https://doi.org/10.1210/jendso/bvab048.1954.

  16. Oyibo SO. Subacute thyroiditis after receivingthe adenovirus-vectored vaccine forcoronavirus disease (COVID-19). Cureus2021;13:e16045. https://doi.org/10.7759/cureus.16045.

  17. Şahin-Tekin M, Şaylısoy S, Yorulmaz G.Subacute thyroiditis following COVID-19vaccination in a 67-year-old male patient:a case report. Hum Vaccin Immunother2021;17:4090-4092. https://doi.org/10.1080/21645515.2021.1947102.

  18. Leber HM, Sant'Ana L, Konichi da Silva NR,Raio MC, Mazzeo T, Endo CM, et al. Acutethyroiditis and bilateral optic neuritis followingSARS-CoV-2 vaccination with coronavac: a casereport. Ocul Immunol Inflamm 2021;29:1200-1206. https://doi.org/10.1080/09273948.2021.1961815.

  19. Chapin-Bardales J, Gee J, Myers T. Reactogenicityfollowing receipt of mRNA-based COVID-19 vaccines. JAMA 2021;325:2201-2202.https://doi.org/10.1001/jama.2021.5374.

  20. Ohsako N, Tamai H, Sudo T, Mukuta T, TanakaH, Kuma K, et al. Clinical characteristicsof subacute thyroiditis classified according tohuman leukocyte antigen typing. J Clin EndocrinolMetab 1995;80:3653-3656. https://doi.org/10.1210/jcem.80.12.8530615.

  21. Centers for Disease, Control and Prevention(CDC). Use of COVID-19 vaccines in the UnitedStates. Atlanta, USA: CDC; 2021. Acceso 17 dediciembre de 2021. Disponible en https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html.




2020     |     www.medigraphic.com